{"title":"常染色体隐性遗传性痉挛性截瘫:一例罕见的家族表型变异","authors":"M. Saban, Tal Shachar","doi":"10.2174/1875692117999201211142908","DOIUrl":null,"url":null,"abstract":"\n\n Hereditary spastic paraplegia is a neurodegenerative disorder\nwith a pure and complex form. More than 50 genetic types are currently known, with different\nages of onset for characteristic symptoms. Data regarding hereditary spastic paraplegia\nremain scarce, and the rare subtype of spastic paraplegia type 5 is no exception.\n\n\n\n This report presents data regarding the case of a single family, from the city of\nDjerba, with five individuals affected with hereditary spastic paraplegia, the largest number\nof spastic paraplegia type 5 mutated family members so far reported in current literature.\n\n\n\nTo emphasize the importance of genetic testing, we retrospectively reviewed a\nfamilial confirmed case of hereditary spastic paraplegia. Clinical features of family members\nwere described.\n\n\n\nThe family presents a large phenotypic variation that, in part, differs from the\nknown phenotypic presentations. Age of onset and clinical manifestation showed interfamilial\nvariations. The alteration found in CYP7B1 (c.1081C>T; p.R361*) may help emphasize\nthe importance of genetic testing and the much-needed treatment options already\nin use in current neurological practice.\n\n\n\n The understanding of the molecular pathways of hereditary spastic paraplegia,\ntogether with the establishment of disease biomarkers, will hopefully lead to better\nand more personalized treatment.\n","PeriodicalId":11056,"journal":{"name":"Current Pharmacogenomics and Personalized Medicine","volume":"62 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Autosomal Recessive Hereditary Spastic Paraplegia: A Rare Case of a Family with Phenotypic Variation\",\"authors\":\"M. Saban, Tal Shachar\",\"doi\":\"10.2174/1875692117999201211142908\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\n Hereditary spastic paraplegia is a neurodegenerative disorder\\nwith a pure and complex form. More than 50 genetic types are currently known, with different\\nages of onset for characteristic symptoms. Data regarding hereditary spastic paraplegia\\nremain scarce, and the rare subtype of spastic paraplegia type 5 is no exception.\\n\\n\\n\\n This report presents data regarding the case of a single family, from the city of\\nDjerba, with five individuals affected with hereditary spastic paraplegia, the largest number\\nof spastic paraplegia type 5 mutated family members so far reported in current literature.\\n\\n\\n\\nTo emphasize the importance of genetic testing, we retrospectively reviewed a\\nfamilial confirmed case of hereditary spastic paraplegia. Clinical features of family members\\nwere described.\\n\\n\\n\\nThe family presents a large phenotypic variation that, in part, differs from the\\nknown phenotypic presentations. Age of onset and clinical manifestation showed interfamilial\\nvariations. The alteration found in CYP7B1 (c.1081C>T; p.R361*) may help emphasize\\nthe importance of genetic testing and the much-needed treatment options already\\nin use in current neurological practice.\\n\\n\\n\\n The understanding of the molecular pathways of hereditary spastic paraplegia,\\ntogether with the establishment of disease biomarkers, will hopefully lead to better\\nand more personalized treatment.\\n\",\"PeriodicalId\":11056,\"journal\":{\"name\":\"Current Pharmacogenomics and Personalized Medicine\",\"volume\":\"62 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Pharmacogenomics and Personalized Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1875692117999201211142908\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacogenomics and Personalized Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1875692117999201211142908","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Autosomal Recessive Hereditary Spastic Paraplegia: A Rare Case of a Family with Phenotypic Variation
Hereditary spastic paraplegia is a neurodegenerative disorder
with a pure and complex form. More than 50 genetic types are currently known, with different
ages of onset for characteristic symptoms. Data regarding hereditary spastic paraplegia
remain scarce, and the rare subtype of spastic paraplegia type 5 is no exception.
This report presents data regarding the case of a single family, from the city of
Djerba, with five individuals affected with hereditary spastic paraplegia, the largest number
of spastic paraplegia type 5 mutated family members so far reported in current literature.
To emphasize the importance of genetic testing, we retrospectively reviewed a
familial confirmed case of hereditary spastic paraplegia. Clinical features of family members
were described.
The family presents a large phenotypic variation that, in part, differs from the
known phenotypic presentations. Age of onset and clinical manifestation showed interfamilial
variations. The alteration found in CYP7B1 (c.1081C>T; p.R361*) may help emphasize
the importance of genetic testing and the much-needed treatment options already
in use in current neurological practice.
The understanding of the molecular pathways of hereditary spastic paraplegia,
together with the establishment of disease biomarkers, will hopefully lead to better
and more personalized treatment.
期刊介绍:
Current Pharmacogenomics and Personalized Medicine (Formerly ‘Current Pharmacogenomics’) Current Pharmacogenomics and Personalized Medicine (CPPM) is an international peer reviewed biomedical journal that publishes expert reviews, and state of the art analyses on all aspects of pharmacogenomics and personalized medicine under a single cover. The CPPM addresses the complex transdisciplinary challenges and promises emerging from the fusion of knowledge domains in therapeutics and diagnostics (i.e., theragnostics). The journal bears in mind the increasingly globalized nature of health research and services.